Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, van der Aart J, van den Bos H, Spierings D, Oukrif D, Novelli M, Chakrabarti T, Rabinowitz AH, Ait Hassou L, Litière S, Kerr DL, Tan L, Kelly G, Moore DA, Renshaw MJ, Venkatesan S, Hill W, Huebner A, Martínez-Ruiz C, Black JRM, Wu W, Angelova M, McGranahan N, Downward J, Chmielecki J, Barrett C, Litchfield K, Chew SK, Blakely CM, de Bruin EC, Foijer F, Vousden KH, Bivona TG; TRACERx consortium; Hynds RE, Kanu N, Zaccaria S, Grönroos E, Swanton C.
Hobor S, et al. Among authors: renshaw mj.
Nat Commun. 2024 Jun 13;15(1):4871. doi: 10.1038/s41467-024-47606-9.
Nat Commun. 2024.
PMID: 38871738
Free PMC article.